NO770898L - Fremgangsm}te til stabilisering av erythrocyter - Google Patents
Fremgangsm}te til stabilisering av erythrocyterInfo
- Publication number
- NO770898L NO770898L NO770898A NO770898A NO770898L NO 770898 L NO770898 L NO 770898L NO 770898 A NO770898 A NO 770898A NO 770898 A NO770898 A NO 770898A NO 770898 L NO770898 L NO 770898L
- Authority
- NO
- Norway
- Prior art keywords
- erythrocytes
- glyoxal
- treated
- formaldehyde
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 34
- 230000006641 stabilisation Effects 0.000 title description 4
- 238000011105 stabilization Methods 0.000 title description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 68
- 210000003743 erythrocyte Anatomy 0.000 claims description 64
- 210000004027 cell Anatomy 0.000 claims description 57
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 47
- 229940015043 glyoxal Drugs 0.000 claims description 36
- 239000000427 antigen Substances 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 238000001514 detection method Methods 0.000 claims description 11
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 11
- 239000001509 sodium citrate Substances 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 10
- 239000012736 aqueous medium Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 230000035931 haemagglutination Effects 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 239000007900 aqueous suspension Substances 0.000 claims 3
- 239000012431 aqueous reaction media Substances 0.000 claims 1
- 238000005534 hematocrit Methods 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 150000001299 aldehydes Chemical class 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000004520 agglutination Effects 0.000 description 6
- 239000000178 monomer Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000834 fixative Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 239000006194 liquid suspension Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010029719 Nonspecific reaction Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 101100459439 Caenorhabditis elegans nac-2 gene Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 229960004279 formaldehyde Drugs 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960000587 glutaral Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
- G01N33/555—Red blood cell
- G01N33/556—Fixed or stabilised red blood cell
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03G—ELECTROGRAPHY; ELECTROPHOTOGRAPHY; MAGNETOGRAPHY
- G03G15/00—Apparatus for electrographic processes using a charge pattern
- G03G15/20—Apparatus for electrographic processes using a charge pattern for fixing, e.g. by using heat
- G03G15/2092—Apparatus for electrographic processes using a charge pattern for fixing, e.g. by using heat using pressure only
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03G—ELECTROGRAPHY; ELECTROPHOTOGRAPHY; MAGNETOGRAPHY
- G03G9/00—Developers
- G03G9/08—Developers with toner particles
- G03G9/087—Binders for toner particles
- G03G9/08702—Binders for toner particles comprising macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
- G03G9/08704—Polyalkenes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/826—Additives, e.g. buffers, diluents, preservatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/667,316 US4136161A (en) | 1976-03-16 | 1976-03-16 | Stabilized erythrocytes and methods therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO770898L true NO770898L (no) | 1977-09-19 |
Family
ID=24677729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO770898A NO770898L (no) | 1976-03-16 | 1977-03-14 | Fremgangsm}te til stabilisering av erythrocyter |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US4136161A (es) |
| AT (1) | AT357689B (es) |
| AU (2) | AU517510B2 (es) |
| BE (1) | BE852482A (es) |
| CA (1) | CA1090700A (es) |
| DE (1) | DE2711489A1 (es) |
| DK (1) | DK110777A (es) |
| ES (1) | ES456913A1 (es) |
| FR (1) | FR2344842A1 (es) |
| IL (1) | IL51662A (es) |
| IT (1) | IT1083729B (es) |
| NL (1) | NL7702861A (es) |
| NO (1) | NO770898L (es) |
| SE (1) | SE7702917L (es) |
| ZA (1) | ZA771553B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2828235C2 (de) * | 1978-06-28 | 1980-04-17 | Kernforschungsanlage Juelich Gmbh, 5170 Juelich | Verfahren und Adsorptionsmittel zur Isolierung und Reindarstellung von Enzymen aus einer Roh-Enzym-Lösung |
| US4202665A (en) * | 1978-11-06 | 1980-05-13 | Albert Einstein College Of Medicine Of Yeshiva University A Division Of Yeshiva University | Detection of hepatitis B surface antigen |
| JPS566161A (en) * | 1979-06-28 | 1981-01-22 | Seikagaku Kogyo Co Ltd | Erythropoietin sensitized latex |
| JPS59192961A (ja) * | 1983-04-15 | 1984-11-01 | Green Cross Corp:The | 血液凝固第「じ」因子測定用試薬 |
| US4939096A (en) * | 1986-09-10 | 1990-07-03 | Idexx, Corp. | Method and apparatus for assaying whole blood |
| US5759774A (en) * | 1988-05-18 | 1998-06-02 | Cobe Laboratories, Inc. | Method of detecting circulating antibody types using dried or lyophilized cells |
| US5008202A (en) * | 1988-11-29 | 1991-04-16 | Sequoia Turner Corporation | Blood diluent for red blood cell analysis |
| WO1992006696A1 (en) * | 1990-10-11 | 1992-04-30 | Innovatsionno-Venchurnaya Firma 'chernovitsky Gorodskoi Tsentr Nauchno-Tekhnicheskogo Tvorchestva Molodezhi 'ort' | Method for obtaining bioactive preparation from blood |
| US5998483A (en) * | 1991-09-20 | 1999-12-07 | Camiener; Gerald W. | Glyoxal-containing preservative compositions |
| EP0627879A1 (en) * | 1991-09-20 | 1994-12-14 | CAMIENER, Gerald, W. | Methods and compositions with aldehyde stabilizing solution |
| US5401625A (en) * | 1993-06-24 | 1995-03-28 | E. K. Industries, Inc. | Histological composition for light microscopy |
| JP6300352B2 (ja) * | 2014-03-31 | 2018-03-28 | シーシーアイ株式会社 | 中性脂肪濃度測定用の標準物質組成物およびその製造方法 |
| AR119906A1 (es) * | 2019-09-05 | 2022-01-19 | Hemanext Inc | Métodos para la conservación de glóbulos rojos reactivos utilizando monóxido de carbono |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL126572C (es) * | 1966-03-24 | |||
| GB1244344A (en) * | 1967-11-13 | 1971-08-25 | Abbott Lab | Hemagglutination testing procedure employing stabilized and potentiated erythrocytes and a method for their preparation |
| US3553310A (en) * | 1967-12-28 | 1971-01-05 | Miles Lab | Immunologically reactive particles |
| US3708572A (en) * | 1969-03-26 | 1973-01-02 | Baxter Laboratories Inc | Infectious mononucleosis diagnostic reagent and method |
| JPS5010374B1 (es) * | 1969-11-10 | 1975-04-21 | ||
| GB1392181A (en) * | 1971-04-16 | 1975-04-30 | Rech Et Dapplications Soc Gen | Fixation of nitrogenous materials |
-
1976
- 1976-03-16 US US05/667,316 patent/US4136161A/en not_active Expired - Lifetime
-
1977
- 1977-03-04 CA CA273,254A patent/CA1090700A/en not_active Expired
- 1977-03-14 IT IT48458/77A patent/IT1083729B/it active
- 1977-03-14 DK DK110777A patent/DK110777A/da not_active Application Discontinuation
- 1977-03-14 NO NO770898A patent/NO770898L/no unknown
- 1977-03-15 IL IL51662A patent/IL51662A/xx unknown
- 1977-03-15 ZA ZA00771553A patent/ZA771553B/xx unknown
- 1977-03-15 AT AT175577A patent/AT357689B/de not_active IP Right Cessation
- 1977-03-15 SE SE7702917A patent/SE7702917L/xx unknown
- 1977-03-15 BE BE175811A patent/BE852482A/xx unknown
- 1977-03-15 FR FR7707676A patent/FR2344842A1/fr active Granted
- 1977-03-15 AU AU26235/77A patent/AU517510B2/en not_active Expired
- 1977-03-15 AU AU23235/77A patent/AU2323577A/en not_active Expired
- 1977-03-16 DE DE19772711489 patent/DE2711489A1/de not_active Withdrawn
- 1977-03-16 ES ES456913A patent/ES456913A1/es not_active Expired
- 1977-03-16 NL NL7702861A patent/NL7702861A/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AT357689B (de) | 1980-07-25 |
| US4136161A (en) | 1979-01-23 |
| AU2323577A (en) | 1978-09-21 |
| BE852482A (fr) | 1977-09-15 |
| DK110777A (da) | 1977-09-17 |
| IL51662A (en) | 1979-11-30 |
| ZA771553B (en) | 1978-10-25 |
| ATA175577A (de) | 1979-12-15 |
| AU517510B2 (en) | 1981-08-06 |
| FR2344842B1 (es) | 1981-01-02 |
| NL7702861A (nl) | 1977-09-20 |
| AU2623577A (en) | 1979-01-04 |
| IL51662A0 (en) | 1977-05-31 |
| CA1090700A (en) | 1980-12-02 |
| DE2711489A1 (de) | 1977-09-22 |
| ES456913A1 (es) | 1978-07-16 |
| IT1083729B (it) | 1985-05-25 |
| FR2344842A1 (fr) | 1977-10-14 |
| SE7702917L (sv) | 1977-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4673871B2 (ja) | 赤血球用懸濁媒体 | |
| NO770898L (no) | Fremgangsm}te til stabilisering av erythrocyter | |
| US20020019053A1 (en) | Hematology control and system for multi-parameter hematology measurements | |
| Eadie et al. | The potential life span and ultimate survival of fresh red blood cells in normal healthy recipients as studied by simultaneous Cr 51 tagging and differential hemolysis | |
| WO1995020429A1 (en) | Density gradient medium for separating cells | |
| EP0161281A4 (en) | STABILIZATION OF INDICATORS TO DETECT ENZYMACTIVITY. | |
| EP0050660B1 (en) | Antibody detection process and reagents therefor | |
| Karpatkin et al. | The platelet factor 3 immunoinjury technique re-evaluated. Development of a rapid test for antiplatelet antibody. Detection in various clinical disorders, including immunologic drug-induced and neonatal thrombocytopenias | |
| Sebring et al. | Detection of fetal hemorrhage in Rh immune globulin candidates. A rosetting technique using enzyme‐treated Rh2Rh2 indicator erythrocytes | |
| US4587222A (en) | Reagent comprising treated red blood cells and methods for detecting rheumatoid factor | |
| US4311690A (en) | Test set and method for the determination of free hormones | |
| US6146901A (en) | Composition for manipulating optical and electrical properties of particles to achieve target values for such properties and methods for using the composition | |
| CN104730231B (zh) | 一种用于荧光免疫定量检测的样本缓冲液及其应用 | |
| US5536643A (en) | Non-radioactive method for determining circulating red cell volume, total blood volume, and red cell survival | |
| KR890000393B1 (ko) | 비루스성 적혈구 응집 반응 시험용 조류(鳥類)고정 적혈구의 보존액 | |
| CA2292595A1 (en) | Anti-coagulation of blood, blood plasma or synovial fluid products | |
| US3925541A (en) | Method of coating stabilized erythrocytes | |
| US7767465B2 (en) | Reduction of platelet interference in plasma assay samples | |
| Kooptzoff | The deterioration during storage of red cell antigens. | |
| Reid et al. | Agglutination of an EDTA blood sample caused by an EDTA-dependent panagglutinin | |
| Beattie | Control of the antigen‐antibody ratio in antibody detection/compatibility tests | |
| Vermylen et al. | A simple method for the instantaneous Quantitation of fibrinogen the FPT-test | |
| JPS60244861A (ja) | 溶血式測定方法及びそれに使用する試薬キツト | |
| Bischoff et al. | Estradiol transport by human red cells | |
| Tucker et al. | The M‐L blood group system and active potassium transport in sheep reticulocytes |